TABLE 1.

Clinical Characteristics of 8 Patients With Vasculitis Associated With TNF-α Inhibitors^a

Patient No.	Age (y)/sex	Conditionb	Anti–TNF-α agent	Duration of treatment (mo)c	Korean algorithm scored	Organ involvement	Cutaneous lesions	Type of vasculitis	Use of anti–TNF-α agent discontinued	Time to resolution (mo)e	Treatment	Outcome
1	54/F	Rheumatoid arthritis	Etanercept	12	9	Cutaneous	Ulcerated lesions, erythematous macules, blisters	CSVV	Yes	1	Prednisone	Complete response
2	70/M	Rheumatoid arthritis	Infliximab	72	9	Cutaneous	Palpable purpura	CSVV	Yes	2	Prednisone, rituximab	Complete response
3	43/F	Rheumatoid arthritis	Etanercept	36	9	Peripheral nerve	None	Neuropathy	Yes	24	Prednisone, cyclophosphamide	Partial response
4	18/F	Crohn disease	Adalimumab	60	9	Cutaneous, peripheral nerve	Palpable purpura	CSVV, neuropathy	Yes	2	Prednisone, methotrexate	Complete response
5	64/F	Rheumatoid arthritis	Infliximab	60	9	Cutaneous	Palpable purpura, ulcerated lesions	CSVV	Yes	1	Prednisone, hydroxychloroquine	Partial response
6	52/M	Ulcerative colitis	Infliximab	24	9	Peripheral nerve	None	Neuropathy	Yes	6	Prednisone, azathioprine	Complete response
7	21/F	Ulcerative colitis	Infliximab	6	6	Cutaneous, kidney	Palpable purpura	HSP	Yes	NAf	Prednisone, mycophenolate mofetil	No response
8	66/F	Ulcerative colitis	Infliximab	2	9	Peripheral nerve	None	Neuropathy	Yes	12	Prednisone, mycophenolate mofetil	Partial response

^aCSVV = cutaneous small-vessel vasculitis; HSP = Henoch-Schönlein purpura; NA = not applicable; TNF-α, = tumor necrosis factor-α.

^bThe underlying condition was quiescent at the time vasculitis developed.

^cBefore development of vasculitis.

^dAdverse drug reaction scores are as follows: 9 or higher for “certain,” 6 to 8 for “probable/likely,” 3 to 5 for “possible,” 1 to 2 for “unlikely,” and less than 0 for “contradictory.”¹²

^eAfter discontinued use of the anti–TNF-α agent.

^fSkin lesions persisted.